Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

Background In an analysis of the primary outcome of this phase 3 trial, patients with early
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-
care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) …

Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

Axicabtagene ciloleucel (axi-cel) is a standard-of-care for patients with relapsed or refractory
(r/r) large B cell lymphoma who have received 2 or more lines of prior therapy. Patients …

Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …